

# OPEXA THERAPEUTICS, INC.

## FORM FWP

(Free Writing Prospectus - Filing under Securities Act Rules 163/433)

Filed 02/12/08

|             |                                                         |
|-------------|---------------------------------------------------------|
| Address     | 2635 TECHNOLOGY FOREST BLVD.<br>THE WOODLANDS, TX 77381 |
| Telephone   | (281) 272-9331                                          |
| CIK         | 0001069308                                              |
| Symbol      | OPXA                                                    |
| SIC Code    | 2834 - Pharmaceutical Preparations                      |
| Industry    | Biotechnology & Drugs                                   |
| Sector      | Healthcare                                              |
| Fiscal Year | 12/31                                                   |

Issuer Free Writing Prospectus  
Filed Pursuant to Rule 433  
Registration Statement No. 333-147167  
February 12, 2008

**Opexa Therapeutics, Inc.**

**Revised Series E Warrant Terms**

Opexa Therapeutics, Inc. ("Opexa") has revised a term of its Series E warrants that it is offering. The revised term is described below.

1. The exercise price of the Series E warrants to be issued by Opexa will be \$\_\_\_\_ (100% of offering price per share of common stock).

Opexa Therapeutics, Inc. has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at <http://www.sec.gov>. Alternatively, Opexa Therapeutics, Inc., any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling 281-272-9331 or by e-mailing [ir@opexatherapeutics.com](mailto:ir@opexatherapeutics.com).